Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 9/20 | 0.44 |
| ▸ | CLK3 | P49761 | 9/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770383 | 0.82 | PDE3B (0.46) | CLK2CLK3DYRK1ATTKLRRK2 | |
| SCHEMBL3766533 | 0.82 | TTK (0.58) | TDO2CLK2DYRK1ATTKPIM1 | |
| SCHEMBL3783350 | 0.81 | DYRK1A (0.48) | CLK2CLK3DYRK1ATTKLRRK2 | |
| SCHEMBL3762138 | 0.76 | CYP1A2 (0.47) | LRRK2FYN | |
| SCHEMBL3775330 | 0.75 | MRGPRX1 (0.47) | LRRK2 | |
| SCHEMBL3771920 | 0.75 | GRM4 (0.56) | FYN | |
| SCHEMBL3769258 | 0.74 | PIM1 (0.42) | CLK2CLK3DYRK1ATTKPIM1 | |
| SCHEMBL3780725 | 0.73 | CLK4 (0.46) | CLK2DYRK1ALRRK2MAPK14MAP2K4 | |
| SCHEMBL3775810 | 0.72 | TTK (0.66) | TDO2CLK2CLK3DYRK1ATTK | |
| SCHEMBL695846 | 0.71 | MAP2K4 (0.41) | TTKPIM1NTRK1HTR7MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | TDO2 4001/4885CLK2 2298/4885CLK3 846/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | TDO2 4007/4885CLK2 2296/4885CLK3 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.